Evolus, Inc. (EOLS) |
| 4.33 0.06 (1.41%) 04-13 16:00 |
| Open: | 4.25 |
| High: | 4.395 |
| Low: | 4.1899 |
| Volume: | 572,808 |
| Market Cap: | 282(M) |
| PE Ratio: | -5.41 |
| Exchange: | NASDAQ Global Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 5.67 |
| Resistance 1: | 4.98 |
| Pivot price: | 4.21 |
| Support 1: | 3.86 |
| Support 2: | 3.21 |
| 52w High: | 12.28 |
| 52w Low: | 3.86 |
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Financials
| EPS | -0.800 |
| Book Value | -0.350 |
| PEG Ratio | 0.00 |
| Gross Profit | 3.030 |
| Profit Margin (%) | -17.38 |
| Operating Margin (%) | -0.32 |
| Return on Assets (ttm) | -10.3 |
| Return on Equity (ttm) | 0.0 |
Company news
Sun, 12 Apr 2026
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
Sat, 11 Apr 2026
How The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target Cuts - Yahoo Finance
Fri, 10 Apr 2026
EOLS Stock Price, Quote & Chart | EVOLUS INC (NASDAQ:EOLS) - ChartMill
Tue, 31 Mar 2026
Evolus management joins Needham virtual healthcare event April 14 - Stock Titan
Thu, 26 Mar 2026
Vanguard disaggregates holdings for Evolus (NASDAQ: EOLS) after internal realignment - Stock Titan
Wed, 18 Mar 2026
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock - Investing.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
